SCHEMBL6577620

SCHEMBL6577620

Oc1cccc2c1OOCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.41
BCL2L1 Q07817 1/20 0.39
BAD Q92934 1/20 0.39
PTGS1 P23219 2/20 0.34
ALDH1A1 P00352 2/20 0.34
ALOX15 P16050 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
HPN P05981 1/20 0.34
CYP3A4 P08684 1/20 0.34
ALOX5 P09917 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
TSHR P16473 1/20 0.34
PDE4A P27815 1/20 0.34
KDR P35968 1/20 0.34
KMT2A Q03164 1/20 0.34
SIRT5 Q9NXA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6700650 0.83 BCL2L1 (0.45) PARP1BCL2L1BADPTGS1ALDH1A1
SCHEMBL3072437 0.79 BCL2L1 (0.38) BCL2L1BADPTGS1ALDH1A1ALOX15
SCHEMBL2052908 0.79 PARP1 (0.56) PARP1BCL2L1BADPTGS1ALDH1A1
SCHEMBL4614930 0.76 PARP1 (0.37) PARP1
SCHEMBL8576724 0.76 PARP1 (0.37) PARP1ALDH1A1L3MBTL1CA1CA2
SCHEMBL9064715 0.76 PARP1 (0.38) PARP1CA1CA2CA12CA9
SCHEMBL7517744 0.72 BCL2L1 (0.48) PARP1BCL2L1BADPTGS1ALDH1A1
SCHEMBL9065117 0.72 PARP1 (0.34) PARP1
SCHEMBL27371497 0.72 PARP1 (0.41) PARP1ALDH1A1TDP1MEN1THRB
SCHEMBL70615 0.72 GABRA1 (0.36) PARP1PTGS1CYP3A4TSHRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390364-B1 ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION WYETH CORP (US) 2004-09-29 EP disclosed
EP-1390364-A1 ARYL-8-AZABICYCLO 3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION Wyeth (US) 2004-02-25 EP disclosed
US-6632824-B2 Have the ability to act at the 5-HT transporter. WYETH 2003-10-14 US disclosed
US-20030032645-A1 Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression WYETH 2003-02-13 US disclosed
WO-2002096906-A1 ARYL-8-AZABICYCLO[3.2.1]OCTANES FOR THE TREATMENT OF DEPRESSION WYETH (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032645-A1 Aryl-8-azabicyclo [3.2.1] octanes for the treatment of depression HTR1A, HTR1D, HTR2C PARP1 983/4885BCL2L1 1585/4885BAD 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.